Marker Therapeutics Inc (MRKR)

[ash111]

MARKET VALUE still a joke-Cash increased 7 times. 1.5m vs 220k. "In Q1 2015, we strengthened our balance sheet by raising additional $2.5M in working capital giving us confidence in our ability to continue developing our products on the path to commercialization. The structure of this financing gives us additional opportunities to raise additional capital through the exercise of short-term and long-term warrants. The strength of our science and development approaches is becoming more widely appreciated, particularly as our clinical program has now generated positive interim data on both clinical programs in Breast and Ovarian Cancer. Also, we are pleased to report that our clinical programs are seeing positive outcomes and we expect further read outs on the data as we approach the annual ASCO meeting (Association of Clinical Oncology) in Chicago at the end of May."

This stock will be trading much higher. imo

TPIV has the best Share Structure from most of biopharma companies.also market cap is still very low (relating other biopharma companies). the Billionaire guy that just took a solid position in the company , solid insiders(including mutual funds/institutions), Primed granted Patents, Added additional working capital, reduced stockholders stockholders’ deficit (from $8.7 million in December 2013 to $2.46 million in the second quarter and further down to $656,000 in the third quarter), closed a $2 million registered direct offering with a fundamental institutional investor and a further $2.5 million in the first quarter of 2015( "giving us confidence in our ability to continue developing our products on the path to commercialization")

and Maybe the most important: "promising data on both clinical programs in Breast and Ovarian Cancer".

TPIV also reported that " all our pre-clinical programs are seeing positive outcomes".

With the new funding the Company is focusing on the following key initiatives:

Entry into Phase II HER2/neu Breast Cancer Trials

Entry into Phase II Triple Negative Cancer Trials and Fast Track & Orphan Drug Status

Produce new PolyStart ™ constructs, in-house, to facilitate collaborative efforts in our current clinical indications and those where others have already indicated interest in combination therapies."

Market potential could reach Billions the coming years per estimations.

Share Structure
Market Value1 $12,402,748 a/o May 21, 2015
Outstanding Shares 32,638,810 a/o May 01, 2015

Up to $10m in funding.all details here: Eastern Capital Limited will receive a standard 5-year warrant that, if exercised, would provide $7.5 million in funding and callable warrants that, under certain market conditions, will provide an additional $7.0 million in capital to TapImmune. Additional warrants, exercisable only to the extent the callable warrants are exercised or called, could provide the Company with a further $10.0 million in funding. H.C. Wainwright & Co. acted as exclusive placement agent for the transaction."

http://finance.yahoo.com/news/tapimmune-receives-1-000-000-123000897.html

TPIV will not need any r/s the coming years.this is super solid (10m is also current market cap.this is way undervalued.check other biopharma companies..)

almost no debt,and almost 10m in funding.institutions banking on her